SEARCH

SEARCH BY CITATION

References

  • 1
    DiMasi JA , Hansen RW , Grabowski HG . The price of innovation: new estimates of drug development costs . J Hlth Econ 2003 ; 22 : 15185 .
  • 2
    Parexel’s Pharmaceutical R & D. Statistical Sourcebook . Parexel , Waltham Massachusetts, USA , 20032004 .
  • 3
    Food and Drug Administration. Innovation or Stagnation. Challenge and Opportunity on the Critical Path to New Medical Products . Food and Drug Administration , Washington DC, USA , 2004 .
  • 4
    Horrobin DF . Modern biomedical research: an internally self-consistent universe with little contact with medical reality? Nature Rev Drug Discovery 2003 ; 2 : 1514 .
  • 5
    Lappin G , Garner RC . Big physics, small doses: the use of AMS and PET in human microdosing of development drugs . Nature Rev Drug Discovery 2003 ; 2 : 23340 .
  • 6
    Lappin G , Garner RC . Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry . Anal Bioanal Chem 2004 ; 378 : 35664 .
  • 7
    Aboagye EO , Price PM , Jones T . In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography . Drug Discovery Today 2001 ; 6 : 293302 .
  • 8
    Bergström M , Grahnén A , Langström B . Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development . Eur J Clin Pharmacol 2003 ; 59 : 35766 .
  • 9
    Committee for Medicinal Products for Human Use . Position Paper on non-clinical safety studies to support clinical trials with a single microdose. EMEA CPMP/SWP/2599/02/Rev 1 , 2004 .
  • 10
    Guidance For Industry . Exploratory IND Studies. Guidance . US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research , Washington DC, USA , 2006 .